Full text
Earnings transcript
Read the complete earnings call transcript.
TWST
Twist Bioscience Corporation
$50.21
0.67
(1.35%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 3.078B |
| Shares Outstanding: | 18.781M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Emily Marine Leproust | |||||
| Full Time Employees: | 923 | |||||
| Address: |
| |||||
| Website: | https://www.twistbioscience.com |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 245,109 | 312,974 | 376,572 |
| Gross Profit | 89,729 | 133,349 | 191,002 |
| EBITDA | -174,151 | -176,705 | -52,098 |
| Operating Income | -217,159 | -220,831 | -136,259 |
| Net Income | -204,618 | -208,726 | -77,670 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 776,403 | 614,323 | 641,861 |
| Total Liabilities | 152,971 | 141,634 | 168,903 |
| Total Stockholders Equity | 623,432 | 472,689 | 472,958 |
| Total Debt | 94,069 | 85,026 | 75,572 |
| Cash and Cash Equivalents | 286,470 | 226,316 | 183,049 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -142,474 | -64,094 | -47,628 |
| Capital Expenditure | -27,779 | -5,076 | -28,004 |
| Free Cash Flow | -170,253 | -69,170 | -75,632 |
| Net Income | -204,618 | -208,726 | -77,670 |
| Net Change in Cash | -90,978 | -60,149 | -43,707 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 754,079.241 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 768,433.153 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 761,950 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -524,601.931 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -514,802.653 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -520,175.945 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 73,166.118 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 74,982.487 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 74,161.921 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 633,551.059 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 645,610.715 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 640,163.796 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 1.240 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 1.250 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 1.220 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Product Portfolio and Industry Positioning: Twist Bioscience operates in the biotechnology industry within the healthcare sector, focusing on synthetic biology and DNA synthesis. The company's description highlights its role in providing high-quality synthetic DNA, positioning it as a leader in a niche, high-growth market.
- Revenue Growth Trends: Analysis of income statements indicates consistent revenue growth over recent years, reflecting strong demand for TWST’s products. This growth aligns with industry trends in biotechnology, where innovation drives market expansion.
- Solid Liquidity Metrics: Balance sheet data shows a healthy level of cash and cash equivalents relative to total current liabilities, supported by a favorable current ratio (TTM). This liquidity provides financial stability and flexibility for operational needs and investments.
- Positive Operating Cash Flow: Cash flow statements reveal positive net cash provided by operating activities, indicating the company’s ability to generate cash from core operations, a critical factor for sustaining growth without excessive reliance on external financing.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about TWST valuation
Is Twist Bioscience Corporation (TWST) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Twist Bioscience Corporation (TWST) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TWST a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TWST trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TWST’s P/E ratio?
You can see TWST’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TWST?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TWST a good long-term investment?
Whether TWST fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TWST
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
1.35
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 23.3 | Year High: | 57.88 | |
| Price Avg 50: | 46.76 | Price Avg 200: | 35.46 | |
| Volume: | 967487 | Average Volume: | 1.305M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeTWST full analysis
Welcome to MARKETSNAP’s SWOT analysis for Twist Bioscience! If you’re a long-term investor looking to dive into innovative biotech plays, you’re in the right place. Today, we’re breaking down Twist Bioscience, a company that’s carving out a unique space in the synthetic biology world. Let’s unpack what makes this company tick, analyze its current standing, and figure out if it’s a potential gem for your portfolio. Stick with me as we explore the strengths, weaknesses, opportunities, and threats, with some…
